The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes.

A method for contraception includes administering to a female daily, in a triphasic dosing regimen during a time period of 21 successive days, an oral combination drug formulation of levonorgestrel (LNG) and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the LNG dose in the first phase is 100 mcg, in the second phase is 125 mcg, and in the third phase is 150 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 25 mcg, and in the third phase is 30 mcg, and wherein the triphasic dosing regimen is followed by 7 days without LNG and EE administration.

The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual.

The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence.

The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments.

The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

A method for providing progestogen only contraception.

A method for providing progestogen only contraception.

The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt.% of estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt.% of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 .Math.g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 .Math.m to 50 .Math.m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt.% of estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt.% of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 .Math.g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 .Math.m to 50 .Math.m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.